TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00271817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ezetimibe/simvastatin + niacin (ER)
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to ezetimibe/simvastatin
Description: ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: niacin (ER) tablet
Description: niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ezetimibe (+) simvastatin
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Niacin (ER)
Description: Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ezetimibe/simvastatin and niacin (ER)
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: ezetimibe and simvastatin
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to niacin (ER)
Description: Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
Study: NCT03767023

Intervention type: OTHER
Intervention: cross sectional

Intervention type: OTHER
Intervention: cross sectional
Study: NCT02954497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical placement of the Jarvik 2015 VAD
Description: The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Placement of Jarvik 2015 VAD
Description: Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
Study: NCT02662621

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Urine samples

Intervention type: OTHER
Group type: OTHER
Intervention: Urine samples
Study: NCT05004636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate (0.3mL) in the block and the other half will receive 0.3 mL of saline in the block.
Study: NCT04375202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 1 MG Oral Tablet
Description: Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
Study: NCT01049685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First-line Antiretroviral Therapy
Description: * Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~* Efavirenz: 01 capsules day, plus NRTI background

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First-line Antiretroviral Therapy
Description: * Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~* Efavirenz: 01 capsules day, plus NRTI background
Study: NCT04772495

Intervention type: GENETIC
Intervention: miRNA
Description: miRNA effect on Multiple sclerosis pathology

Intervention type: GENETIC
Intervention: miRNA
Description: miRNA effect on Multiple sclerosis pathology
Study: NCT02581202

Intervention type: DRUG
Intervention: lopinavir/ritonavir
Description: tablet

Intervention type: DRUG
Intervention: lamivudine
Description: tablet
Study: NCT01632462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks.
Study: NCT02613962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy or surgical resection of tumor and blood sampling
Study: NCT01480336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Plus Ranolazine
Description: Ranolazine 500mg by mouth twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiodarone with Placebo
Description: stabel dose of amiodarone as prescribed by cardiologist
Study: NCT04133467

Intervention type: OTHER
Intervention: scalp block
Description: intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
Study: NCT04141384

Intervention type: DEVICE
Group type: OTHER
Intervention: Modular Interactive Tiles System, MITS
Description: The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
Study: NCT00978211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTA-TOC Treatment
Description: Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment.
Study: NCT01473082

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA Augmentation (Synthes)
Description: Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA (Synthes)
Description: Proximal Femoral Nail Antirotation (PFNA)
Study: NCT02488369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET / CT
Study: NCT00718783

Intervention type: OTHER
Intervention: Tissue samples taken from retinoblastoma
Description: Tissue banking

Intervention type: OTHER
Intervention: 5 ml peripheral blood
Description: White blood cells will be isolated from the blood sample as a source of genomic DNA.
Study: NCT01425008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
Study: NCT02097914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational print materials and coaching call
Description: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
Study: NCT00333359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 (GEn)
Description: 1200 mg XP13512, orally, once daily for 52 weeks
Study: NCT03927274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
Study: NCT04368728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2SA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2SA
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2SA
Description: Intramuscular injection
Study: NCT02148965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise / Physical Activity
Description: Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
Study: NCT04451421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change of standing Angle
Description: Change the patient's standing Angle by using an electric bed
Study: NCT02922374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
Study: NCT04086394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Nerve Block
Description: Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Surgery without Nerve Block
Description: Patient's underwent indicated procedure without regional pectoralis nerve block
Study: NCT00520884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin Infusion - Healthy
Description: At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin Infusion - Frail
Description: At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion -Healthy
Description: At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion - Frail
Description: At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
Study: NCT03284671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bifocal stimulation with tDCS
Description: Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
Study: NCT04481984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Hand exercise
Description: Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Care advice
Description: Patients received care advice including avoiding cold exposure and trauma.
Study: NCT02998775

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Study: NCT01745250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Lips
Description: Lip treatment of both upper and lower lip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvederm Ultra Smile
Description: Lip treatment of both upper and lower lip
Study: NCT03852251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Subjects will receive AK104 in combination with oxaliplatin and capecitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
Study: NCT03217006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single arterial graft
Description: This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafting
Description: This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
Study: NCT02833974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035 Nasal Spray Solution
Description: GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray Solution
Description: Nasal Spray Solution as for GSK2245035 without active ingredient.
Study: NCT04289337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined probiotics (1)
Description: Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined probiotics (2)
Description: Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined heat-killed probiotics (1)
Description: Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined heat-killed probiotics (2)
Description: Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic metabolites
Description: Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
Study: NCT02232802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium
Description: comparison of bioavailability of generic Enoxaparin Sodium and Clexane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium
Description: comparison of bioavailability of generic Enoxaparin Sodium and Clexane
Study: NCT01579188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: two injections of normal saline injected in the same manner as the experimental drug, GV1001
Study: NCT03902509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: pirfenidone capsule made in China

Intervention type: DRUG
Group type: OTHER
Intervention: basic treatment
Description: glucocorticoid and expectant treatment etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic treatment
Description: glucocorticoid and expectant treatment etc.
Study: NCT01556607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 24 hour period at 3 visits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo